Study Evaluating the Safety and Tolerability of L-377202

Inclusion Criteria: * Patient is at least an 18-year-old male and has histologically documented, progressive carcinoma of the prostate which is refractory to hormonal manipulation. Progressive disease may be documented by new lesions on bone scan, increase in radiologically measurable disease, or an increase in PSA (at least 50% increase from nadir confirmed twice and measured at least 2 weeks apart.) * An appropriate interval of time has passed since alteration of any hormonal therapy (e.g., 4 weeks for steroids, LHRH agonists, flutamide or megestrol acetate and 6 weeks for nilutamide and bicalutamide). * Patient has a serum PSA of 20 ng/mL or higher. * Patient has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2. * Patients has a life expectancy of \>3 months. * Patient understands and agrees to participate in the study by providing written informed consent. Exclusion Criteria: * Patient is mentally or legally incapacitated at the time of the study or has a history (less than 5 years prior to entry) of drug or alcohol abuse or is currently a user (including "recreational use") of any illicit drugs. * Patient has known HIV or a known HIV-related malignancy. * Patient has participated in another study (including FDA approved drugs for a non-FDA approved indication) of an investigational agent within the last 4 weeks. * Patient requires treatment or is anticipated to require treatment with Cyclosporine, Phenobarbital, phenytoin, or streptozocin. * P…